Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | FASN | P49327 | 1/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.41 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3472164 | 0.98 | RXRA (0.49) | RXRANR1H2NR1H3HPGDMAPK1 | |
| SCHEMBL3470736 | 0.89 | RXRA (0.56) | RXRANR1H2NR1H3HPGDMAPK1 | |
| SCHEMBL3472549 | 0.87 | RXRA (0.56) | RXRANR1H2NR1H3HPGDMAPK1 | |
| SCHEMBL3473198 | 0.86 | RXRA (0.55) | RXRANR1H2NR1H3HPGDMAPK1 | |
| SCHEMBL3471325 | 0.85 | RXRA (0.52) | RXRANR1H2NR1H3HPGDMEN1 | |
| SCHEMBL3469858 | 0.84 | MEN1 (0.53) | RXRANR1H2NR1H3CACNB4CACNA1A | |
| SCHEMBL3470730 | 0.82 | RXRA (0.52) | RXRANR1H2NR1H3MALT1NR3C2 | |
| SCHEMBL3471233 | 0.82 | RXRA (0.56) | RXRANR1H2NR1H3SMN1; SMN2ALDH1A1 | |
| SCHEMBL3472038 | 0.82 | RXRA (0.58) | RXRANR1H2NR1H3SMN1; SMN2ALDH1A1 | |
| SCHEMBL27717009 | 0.82 | CACNB4 (0.49) | HPGDMAPK1SMPD1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-1910307-A1 | PYRAZOLE BASED LXR MODULATORS | Exelixis, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007002559-A1 | PYRAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002559-A1 | PYRAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331295-A1 | MODULATORS OF LXR | NR1H2, NR1H3, NR1H4 | RXRA 18/4885NR1H2 1/4885NR1H3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.